Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 36,870 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the sale, the insider owned 87,157 shares of the company’s stock, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total value of $18,882.58.

Beta Bionics Trading Down 4.8%

Shares of NASDAQ BBNX opened at $16.59 on Friday. The company has a market cap of $746.38 million, a price-to-earnings ratio of -10.05 and a beta of 3.37. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The stock has a 50-day moving average price of $17.30 and a two-hundred day moving average price of $13.78.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, sell-side analysts predict that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Truist Financial raised their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. UBS Group initiated coverage on Beta Bionics in a research note on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price target for the company. Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. William Blair began coverage on Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, The Goldman Sachs Group boosted their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: Several firms reminded investors of the November 3, 2026 deadline to seek lead-plaintiff status in a securities class action covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. Robbins LLP class action notice
• Negative Sentiment: The allegations contend that Beta Bionics and certain officers misled investors about the safety, efficacy, and regulatory status of its iLet insulin pump. The complaints reportedly focus on disclosures concerning an FDA Warning Letter, quality-system “non-conformities,” and allegedly unreported customer complaints involving potentially life-threatening hypoglycemia. SueWallSt shareholder alert
• Negative Sentiment: Insider Mark Hopman sold 36,870 shares for approximately $680,620, reducing his direct ownership by about 29.7%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the negative signaling effect. Beta Bionics insider transaction
• Neutral Sentiment: Reported short interest was zero as of September 10, unchanged from the prior period, with a zero-day short-interest ratio. This data point provides no evidence of meaningful short selling, although the zero figures may reflect incomplete or anomalous reporting.

Hedge Funds Weigh In On Beta Bionics

Hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC lifted its holdings in Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after buying an additional 240,000 shares during the period. BlackRock Inc. acquired a new stake in Beta Bionics during the 2nd quarter worth about $52,340,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Beta Bionics during the 4th quarter worth about $40,437,000. Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the 1st quarter worth about $5,518,000. Finally, Y Intercept Hong Kong Ltd raised its position in shares of Beta Bionics by 4,236.8% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock worth $4,868,000 after acquiring an additional 474,651 shares in the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.